中华临床营养杂志
中華臨床營養雜誌
중화림상영양잡지
CHINESE JOURNAL OF CLINICAL NUTRITION
2010年
4期
235-239
,共5页
益生菌%黏蛋白%实验性结肠炎%复发
益生菌%黏蛋白%實驗性結腸炎%複髮
익생균%점단백%실험성결장염%복발
Probiotics%Mucin%Experimental colitis%Recurrence
目的 观察黏蛋白分泌在双歧三联活菌减轻小鼠结肠炎复发中的作用.方法 BALB/c小鼠分为双歧三联活菌干预组(BIFICO组)、阴性对照组[三硝基苯磺酸(TNBS)组]及正常对照组.BIFICO组及TNBS组小鼠于实验前5 d起每日分别予双歧三联活菌混悬液或磷酸盐缓冲液灌胃,实验当日以1.5%TNBS/50%乙醇溶液(125 mg/kg)给予第1次灌肠,实验第5天于BIFICO组及TNBS组分别随机处死一部分小鼠,剩余小鼠以2.25%TNBS/45%乙醇溶液(180 mg/kg)给予第2次灌肠.第7天实验结束时处死所有小鼠.实验过程中监测疾病活动指数(DAI)变化,行结肠炎症评分,并以免疫组化方法检测结肠黏膜内MUC2的表达.结果 通过两次TNBS/乙醇溶液灌肠成功模拟了小鼠结肠炎复发.BIFICO组小鼠在第2次TNBS/乙醇溶液灌肠后,其DAI评分(1.39±0.68)及结肠炎症组织学评分(2.11±0.78)均明显低于TNBS组(分别为2.39±0.73及3.22±0.97)(P=0.003,P=0.03);实验第5天第2次灌肠前处死的BIFICO组小鼠结肠黏膜内MUC2评分(8.67±0.87)高于TNBS组(7.86±1.10)(P=0.042).结论 双歧三联活菌可能通过促进黏膜内MUC2分泌从而增强黏膜屏障功能,进而减轻小鼠结肠炎复发的严重程度.
目的 觀察黏蛋白分泌在雙歧三聯活菌減輕小鼠結腸炎複髮中的作用.方法 BALB/c小鼠分為雙歧三聯活菌榦預組(BIFICO組)、陰性對照組[三硝基苯磺痠(TNBS)組]及正常對照組.BIFICO組及TNBS組小鼠于實驗前5 d起每日分彆予雙歧三聯活菌混懸液或燐痠鹽緩遲液灌胃,實驗噹日以1.5%TNBS/50%乙醇溶液(125 mg/kg)給予第1次灌腸,實驗第5天于BIFICO組及TNBS組分彆隨機處死一部分小鼠,剩餘小鼠以2.25%TNBS/45%乙醇溶液(180 mg/kg)給予第2次灌腸.第7天實驗結束時處死所有小鼠.實驗過程中鑑測疾病活動指數(DAI)變化,行結腸炎癥評分,併以免疫組化方法檢測結腸黏膜內MUC2的錶達.結果 通過兩次TNBS/乙醇溶液灌腸成功模擬瞭小鼠結腸炎複髮.BIFICO組小鼠在第2次TNBS/乙醇溶液灌腸後,其DAI評分(1.39±0.68)及結腸炎癥組織學評分(2.11±0.78)均明顯低于TNBS組(分彆為2.39±0.73及3.22±0.97)(P=0.003,P=0.03);實驗第5天第2次灌腸前處死的BIFICO組小鼠結腸黏膜內MUC2評分(8.67±0.87)高于TNBS組(7.86±1.10)(P=0.042).結論 雙歧三聯活菌可能通過促進黏膜內MUC2分泌從而增彊黏膜屏障功能,進而減輕小鼠結腸炎複髮的嚴重程度.
목적 관찰점단백분비재쌍기삼련활균감경소서결장염복발중적작용.방법 BALB/c소서분위쌍기삼련활균간예조(BIFICO조)、음성대조조[삼초기분광산(TNBS)조]급정상대조조.BIFICO조급TNBS조소서우실험전5 d기매일분별여쌍기삼련활균혼현액혹린산염완충액관위,실험당일이1.5%TNBS/50%을순용액(125 mg/kg)급여제1차관장,실험제5천우BIFICO조급TNBS조분별수궤처사일부분소서,잉여소서이2.25%TNBS/45%을순용액(180 mg/kg)급여제2차관장.제7천실험결속시처사소유소서.실험과정중감측질병활동지수(DAI)변화,행결장염증평분,병이면역조화방법검측결장점막내MUC2적표체.결과 통과량차TNBS/을순용액관장성공모의료소서결장염복발.BIFICO조소서재제2차TNBS/을순용액관장후,기DAI평분(1.39±0.68)급결장염증조직학평분(2.11±0.78)균명현저우TNBS조(분별위2.39±0.73급3.22±0.97)(P=0.003,P=0.03);실험제5천제2차관장전처사적BIFICO조소서결장점막내MUC2평분(8.67±0.87)고우TNBS조(7.86±1.10)(P=0.042).결론 쌍기삼련활균가능통과촉진점막내MUC2분비종이증강점막병장공능,진이감경소서결장염복발적엄중정도.
Objective To investigate the role of mucins secretion in the process that bifid triple viable capsule attenuates the recurrence of murine experimental colitis. Methods Mice were randomly allocated into BIFICO group (gavage with bifid triple viable capsule), 2,4,6-trinitrobenzenesulfonic acid (TNBS) group (gavage with phosphate-buffered saline), and normal control group. Intrarectal TNBS/ethanol challenge was given to mice on Day 0 followed by rechallenge on Day 5 ( 125 mg/kg and 180 mg/kg, respectively). On Day 5 several mice in both groups were randomly sacrificed before the second TNBS challenge and the remaining mice were sacrificed on Day 7. Disease activity index (DAI) was measured throughout the experiment. Inflammatory score was evaluated and MUC2 expression was determined using immunohistochemistry method. Results Recurrence of colitis was successfully simulated by challenging mice with two times of TNBS/ethanol solution. Compared with the TNBS group, DAI ( 1.39 ± 0. 68 vs. 2.39 ± 0.73, P = 0.003) and inflammatory score (2. 11 ± 0.78 vs. 3.22 ± 0. 97,P =0.03) were significantly decreased in BIFICO group after the second TNBS challenge. BIFICO administration significantly increased MUC2 expression (8. 67 ± 0. 87 vs. 7.86 ± 1.10, P = 0. 042 ) in BIFICO group compared with TNBS group before the second TNBS challenge. Conclusion Bifid triple viable capsule may enhance mucosal barriers by promoting mucins secretion, and thus attenuates the recurrence of murine colitis.
